Skip to main content
Smart Investors Daily
AA

NASDAQ · AARD

Aardvark Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$0.92

Down-$0.08 (-7.74%)

Updated Nov 22, 2026, 7:37 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
271.95M
P/E ratio
-5.56
Dividend yield
0.00%
52-week range
$0.90 – $16.60
Volume
241.08K
Avg. volume
188.95K

Price performance · AARD

AARD price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

AARD closed at $0.92 after 20 trading sessions, down 14.57% for the selected period.

Last close
$0.92
Period change
-14.57%
Period low
$0.91
Period high
$1.59
Daily close
View OHLC price history
AARD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$1.00$1.06$0.90$0.9226241.08K
Nov 19, 2026$0.96$1.10$0.95$1.00486.55K
Nov 18, 2026$1.16$1.21$0.9062$0.91530.04K
Nov 17, 2026$1.24$1.3799$1.10$1.15475.5K
Nov 16, 2026$1.33$1.48$1.21$1.26215.22K
Nov 13, 2026$1.58$1.70$1.31$1.33403.06K
Nov 12, 2026$1.58$1.615$1.51$1.52249.8K
Nov 11, 2026$1.35$1.6799$1.34$1.59388.41K
Nov 10, 2026$1.32$1.4399$1.29$1.37242.69K
Nov 9, 2026$1.21$1.42$1.1705$1.35686.07K
Nov 6, 2026$1.10$1.18$1.09$1.17221.84K
Nov 5, 2026$1.18$1.2312$1.095$1.11375.89K
Nov 4, 2026$1.25$1.28$1.169$1.26216.5K
Nov 3, 2026$1.22$1.29$1.21$1.23267.93K
Nov 2, 2026$1.37$1.396$1.20$1.20345.53K
Oct 30, 2026$1.39$1.46$1.33$1.36467.6K
Oct 29, 2026$1.48$1.53$1.3618$1.44955.89K
Oct 28, 2026$1.22$1.59$1.1756$1.512.03M
Oct 27, 2026$1.09$1.39$1.09$1.304.28M
Oct 26, 2026$1.245$1.39$0.93$1.084.96M

Latest AARD news

The latest Smart Investors Daily articles mentioning AARD.

AARD research

Overview

Company profile and research snapshot.

Company profile

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$21.00
Implied upside
—
Analysts
—
AARD recent ratings
DateFirmRatingTarget
Oct 27, 2026Jones TradingBuy—
Oct 26, 2026HC Wainwright & Co.Neutral—
Oct 19, 2026HC Wainwright & Co.Neutral—
Sep 24, 2026RBC CapitalSector Perform—
Jul 20, 2026HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Mar 2, 2026

Crude Oil Rises Sharply; Sealed Air Posts Upbeat Earnings

Dow Jones down 0.46% amid Iran-U.S. conflict, NASDAQ down 0.22% and S&P 500 down 0.39%. Energy sector up 1.8%, consumer discretionary down 1.7%. Sealed Air Corp beats earnings expectations. The Dow Jones is down 0.46%, NASDAQ is down 0.22%, and S&P 500 is down 0.39%. Energy sector up 1.8% while consumer discretionary is down 1.7%. Sealed Air Corp surpasses earnings expectations.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.